This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.

Histopathological characterisation of NHL using novel T-cell markers

  • Research type

    Research Study

  • Full title

    Histopathological characterisation of non-hodgkin's lymphoma using novel T-cell markers

  • IRAS ID

    161081

  • Contact name

    Matthew Ahearne

  • Contact email

    mja40@le.ac.uk

  • Duration of Study in the UK

    10 years, 0 months, 1 days

  • Research summary

    There have been significant advances in our understanding of the role and function of T-cells during the normal immune response including the identification of new subsets. These developments are potentially important to better understand the biology of both T-cell and B-cell lymphoma.
    Understanding the exact type of T-cell that a lymphoma has developed from is now possible using new markers of T-cell subsets. This is important as it allows the proposal of a new classification of T-cell lymphoma based on biologically similar patient cohorts. In addition there are many new drugs in development that specifically target key T-cell pathways that are likely to deliver potential benefits to patients with T-cell lymphoma. It is important to be able to characterise the expression of these T-cell pathways in individual cases so that the right patients are selected for the most suitable treatment in future clinical trials.
    T-cells also play an important role in the microenvironment of B-cell lymphoma and have previously been shown to predict clinical outcome. However, the importance of novel T-cell markers recently identified has not yet been studied. We propose to measure the frequency and distribution of stimulatory and regulatory T-cell subsets in B-cell lymphoma, specifically a low-grade indolent type, marginal zone lymphoma, and diffuse large B-cell lymphoma, a high-grade aggressive disease, and to correlate these findings with patient outcomes. These results may propose new treatment approaches in these diseases using novel immunomodulatory drugs.

  • REC name

    East Midlands - Derby Research Ethics Committee

  • REC reference

    14/EM/1176

  • Date of REC Opinion

    31 Oct 2014

  • REC opinion

    Further Information Favourable Opinion